Neuralink restores ALS speech for Kenneth
- Neuralink said an amyotrophic lateral sclerosis patient named Kenneth can now communicate through its VOICE trial, using an implanted brain-computer interface that turns intended speech signals into text and synthetic speech. - Neuralink’s trial page lists VOICE as ClinicalTrials.gov study NCT07224256, an early feasibility study with estimated enrollment of six adults with severe speech impairment and impaired upper-limb function. - The system remains investigational, with no FDA approval or published trial results yet, even as Neuralink says multiple ALS and spinal-cord-injury participants have received implants. (clinicaltrials.gov)
Neuralink says a man with amyotrophic lateral sclerosis, or ALS, is using its brain implant to turn intended speech into audible words. (neuralink.com) (youtube.com) The patient, identified by Neuralink as Kenneth, was diagnosed with ALS in 2024 and later lost the ability to speak easily enough for phone calls and short conversations. (youtube.com) (moneycontrol.com) Speech starts in the brain before it reaches the mouth, tongue and voice box. Neuralink’s speech-restoration page says its implant is designed to record those brain signals and decode them into text or direct speech output. (neuralink.com) That is the basic idea behind a brain-computer interface: read electrical activity from the brain and translate it into a digital command. Neuralink says the N1 implant is a skull-mounted, wireless, rechargeable device connected to electrode threads placed in the brain by its R1 robot. (clinicaltrials.gov) (neuralink.com) Kenneth’s case is part of Neuralink’s VOICE study, which ClinicalTrials.gov lists as an early feasibility trial for adults with severe, irreversible speech-production impairment and impaired upper-limb function. (clinicaltrials.gov) The federal trial registry lists estimated enrollment at six participants, a study start date of October 3, 2025, primary completion in October 2028, and final completion in October 2031. (clinicaltrials.gov) Neuralink’s own trial page says the first participant received an implant in January 2024 and that multiple ALS and spinal cord injury participants have since received the N1 implant. (neuralink.com) The company also said on May 1, 2025 that the Food and Drug Administration granted Breakthrough Device Designation for speech restoration, a program meant to speed review of devices for serious conditions. (neuralink.com) Neuralink’s January 28, 2026 update said it had 21 trial participants, which it calls “Neuralnauts,” enrolled across studies worldwide. That broader count covers more than the VOICE study and includes its Telepathy program for computer control. (neuralink.com) (clinicaltrials.gov) What Neuralink has shown so far is a company demonstration and trial description, not a peer-reviewed clinical paper. Its YouTube video says the devices are investigational, not commercially available, and not approved by the Food and Drug Administration. (youtube.com) (clinicaltrials.gov) For Kenneth, the immediate change is simple to describe: Neuralink says he can communicate again without relying on whatever speech ALS left behind. For everyone else, the next test is whether the company can publish safety and performance data from more than one patient. (youtube.com) (clinicaltrials.gov)
